Alpha-1-antitrypsin - Takeda
Alternative Names: A1PI - Takeda; Alpha 1-antitrypsin - Takeda; Alpha1-PI - Takeda; Aralast; Aralast NP; RespitinLatest Information Update: 05 Nov 2023
At a glance
- Originator Alpha Therapeutic Corporation
- Developer Takeda
- Class Acute-phase proteins; Alpha globulins; Anti-inflammatories; Antiallergics; Antihyperglycaemics; Blood proteins; Secretory proteinase inhibitory proteins; Serpins
- Mechanism of Action Serine endopeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Alpha 1-antitrypsin deficiency
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 03 Jun 2016 Baxalta has been acquired and merged into Shire
- 26 Nov 2004 Data presented at the 70th Annual Meeting of the American College of Chest Physicians (CHEST-2004) have been added to the Respiratory Tract Disorders therapeutic trials section